European PsychiatryJune 23, 2026Maximilian Preiß, Valentin Popper, Luna Helene Charlotte Faber et al.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Esketamine has demonstrated efficacy in treatment-resistant depression (TRD), but medium-term real-world functional outcomes remain understudied. This study described 6-month depressive symptoms and functional trajectories during routine esketamine treatment, focusing on functional outcomes and remission correlates. In this prospective multicenter study, 60 patients with TRD initiating...
Introduction MM120 (lysergide D-tartrate, a formulation of LSD) is under development as a potential treatment for generalized anxiety and major depressive disorders. How psychedelic drugs interact at the TrkB receptor, a key target of neuroplasticity, is not reported. Objectives The study evaluated binding and functional activity of known serotonergic psychedelic compounds and SRI fluoxetine at...
European PsychiatryJune 1, 2026V. Fournier, André Kuntz, Rafik Bouzegaou et al.
Introduction As the number of treatment resistant patient in the psychiatric field has been growing over the last decades, there is a clear need for new therapeutic options. Over several years, the field of psychedelic assisted psychotherapy has been rapidly developing. In this scope ketamine assisted psychotherapy (KAP) has come into psychiatric use to treat depression resistant depression,...
Introduction Treatment-resistant depression (TRD) represents a major challenge in psychiatry. Nearly one-third of patients with major depressive disorder fail to achieve remission despite adequate antidepressant therapy, and about 30% attempt suicide during their lifetime. Given this elevated risk, identifying treatments that rapidly reduce depressive symptoms and suicidality while improving...
Introduction Aphantasia, the inability to voluntarily generate mental visual images, may influence emotional processing and memory encoding. While its effects on memory and cognition have been studied, its role in traumatic memory and PTSD remains underexplored. Understanding how aphantasia interacts with PTSD, depression, and social phobia is crucial, underscoring the need for further...
Introduction Ketamine therapy for treatment-resistant depression has a well-established rapid antidepressant effect for acute symptom management. However, there is far less research on the efficacy of long-term maintenance therapy for relapse prevention. Objectives To examine the utility of long-term maintenance therapy with ketamine infusions delivered in a naturalistic treatment setting....
Introduction Research on psychedelic compounds has grown quickly in the past decade. Yet molecule-specific, quantitative summaries are scattered, making it hard to see how interest differs by compound or over time. Objectives To quantify PubMed-indexed publications on ketamine, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), psilocybin, and psilocin; to describe annual trends...
Introduction Current antidepressants (SSRIs/SNRIs) face limitations including delayed onset (4–6 weeks) and modest efficacy (~50% response rates), while serotonergic psychedelics show rapid antidepressant potential via 5-HT2A agonism and synaptic plasticity but are hindered by hallucinogenic activity and 5-HT2B-mediated cardiotoxicity. Objectives To address these challenges, we characterize...
Introduction Sleep paralysis as a form of parasomnia is associated with poor sleep habits and perceived poor sleep quality (Duarte et al., 2023). Its prevalence in medical students ranges from 16% (Penn et al., 1981) up to 41% (Duarte et al., 2023) with 70% of females reporting experiencing sleep paralysis (Muzammil et al., 2023). Although this disorder does not necessarily testify to the...
Introduction Background: Individuals in the recovery phase of schizophrenia often face persistent challenges including residual symptoms, emotional dysregulation, cognitive deficits, and high relapse rates. Mindfulness-Based Cognitive Therapy (MBCT), effective in mood disorders, shows promise as an adjunctive intervention but requires rigorous evaluation in schizophrenia recovery.Background:...
Treatment-resistant depression (TRD), a persistent condition impacting up to 30% of patients with major depressive disorder, carries substantial personal and economic burden. There remains an unmet need for therapies that provide both rapid and durable improvements in TRD. Preliminary clinical trials indicate that GH001, a synthetic, inhalable formulation of mebufotenin, has the potential for...
Introduction Psychedelic-assisted psychotherapy has re-emerged as a frontier of psychiatry, offering transformative potential for conditions resistant to conventional treatment. Personality disorders—particularly Borderline Personality Disorder (BPD)—are marked by affective instability, interpersonal dysfunction, and maladaptive relational patterns that often limit therapeutic progress. MDMA’s...
Introduction Cannabis consumption has rapidly increased in Delaware due to the legalization of recreational use. There is limited research, however, investigating the links between cannabis use and cognition in older adults. Objectives The objective of this study is to represent the first population-level analysis of cannabis use and subjective cognitive decline (SCD) in older adults in First...
Introduction Suicidal crisis represents a major psychiatric emergency, often occurring in the context of mood disorders and requiring rapid, effective interventions. Traditional antidepressant treatments usually have a delayed onset of action, underscoring the need for fast-acting therapeutic alternatives. In recent years, ketamine—an NMDA receptor antagonist—has emerged as a promising option...
European PsychiatryJune 1, 2026O. Płaza, Robert Madejek, M. M. Dutsch-Wicherek et al.
Introduction Treatment-resistant depression (TRD), which affects about 30% of patients with major depressive disorder, emerges when patients do not respond adequately to at least two antidepressant trials of proper dose and duration. The EMA approved esketamine nasal spray, the first registered psychedelic medication, in 2019 for TRD treatment. In July 2023, Poland launched B.147, the country’s...
Introduction Ketamine and esketamine exert rapid antidepressant and dissociative effects, and the growing clinical use of intranasal esketamine for depression opens the possibility of large-scale electroencephalography (EEG) studies to explore their mechanisms through a non-invasive approach. However, understanding the neurophysiological basis of these effects requires a clear synthesis of...
Introduction TBI patients often suffer from severe, treatment-resistant depression and PTSD. Ketamine shows promise in non-TBI populations, but its efficacy in TBI patients needs exploration for efficacy and tolerability. Objectives Evaluate ketamine’s clinical effectiveness and safety (PHQ-9, GAD-7, PCL-5 scores) in post-TBI patients, comparing IM, intranasal, and oral routes. Methods Design:...
Introduction In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments of antidepressants. Esketamine (the S-enantiomer of ketamine) nasal spray, administered in combination with either a selective serotonin reuptake inhibitor (SSRI) or a serotonine-norepinephrine reuptake inhibitor (SNRI), is the only treatment approved in Europe...
Introduction Ketamine-assisted therapy shows rapid benefit in treatment-resistant depression, anxiety, and PTSD (Walsh et al. BJPsych Open 2022;8:e19). The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a unique 12-week program that combines 12 Community of Practice (group therapy) sessions and three ketamine medicine sessions (Tsang et al. Ther Adv Psychopharmacol...
Introduction Suicide is a leading cause of death in the psychiatric population. The existing modes of treatment (pharmacological and psychotherapeutic) for suicidality are effective but have longer onset, this delay causing a dangerous therapeutic gap in an acute crisis. We compare the two fast-acting treatments, the newer psychopharmacological agent Ketamine and well-established...
Introduction Creative arts therapies, particularly drama therapy techniques, are useful in psychotherapy Objectives We aim to show how the creative arts can be used in the treatment of psychosis and in training people about the experience of psychosis. Methods The techniques can be used in one-on-one appointments or in groups. Useful approaches include the client’s making figures to represent...
Introduction Intranasal esketamine has emerged as an innovative option for the management of treatment-resistant depression (TRD), offering a novel mechanism of action and rapid antidepressant effects. However, evidence regarding the clinical trajectory after treatment discontinuation remains limited, raising questions about the durability of its therapeutic benefits and the optimal maintenance...
Introduction MDMA (3,4-methylenedioxymethamphetamine)–assisted therapy has gained growing scientific attention as a potential treatment for post-traumatic stress disorder and other mental health conditions. Although clinical studies suggest potential benefits, concerns remain regarding cardiovascular safety, methodological rigor, and variability in psychotherapeutic support (Singh et al . CNS...